Relationship Between Circulating Tumor Cell Cultures' Treatment Response and Clinical Outcomes

Cancer Clinical Trial

Official title:

LCCC 1938: Investigating the Relationship Between Circulating Tumor Cell Cultures Treatment Response and Clinical Outcomes

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04280640
• Other study ID #: LCCC1938
• Status: Withdrawn
• Start date: June 2021
• Est. completion date: June 2023

Study information

• Verified date: October 2021
• Source: UNC Lineberger Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this prospective, non-randomized, single-center pilot exploratory study is to investigate whether established circulating tumor cell (CTC) cultures have a similar response to targeted therapy treatment as the in vivo (patients') disease.

Description:

This study will isolate circulating tumor cells (CTCs) from blood samples taken from patients with liver and/or lung metastases who will receive systemic treatments. The CTCs will be cultured and given the same treatment as the patient received. The main goals of this project are 1) to assess CTC cultures' treatment response and compare the in vitro response to the clinical response, and 2) determine the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of CTC cultures' response in predicting clinical response including complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD).

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: June 2023
• Est. primary completion date: June 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with a metastatic solid tumor malignancy with either liver and/or lung metastasis. Patients with newly diagnosed metastatic disease who have not had systemic therapy or are progressing on systemic therapy fitting one of the following cohorts:

• Patients had a tumor or liquid biopsy with molecular analysis (genomic analysis or other type of molecular characterization) resulting in a therapeutic target with planned targeted therapy by the patient's treating physician.

• Gastric cancer patients who have failed the first and second line chemotherapy.

• Bladder cancer patients (with liver and/or lung metastasis) who will receive systemic treatment.

• Scheduled to initiate systemic treatment for management of their disease. The systemic treatment will be either cytotoxic chemotherapy or targeted therapy but not checkpoint inhibitor immunotherapy.

• =18 years of age

• Written informed consent obtained and signed

• Able to have blood collection without excessive difficulty

Exclusion Criteria:

• Patient unwilling or unable to complete informed consent

• Currently pregnant or lactating women

• Physical or psychological inability to complete sample collection for any reason including but not limited to: inability to tolerate any study procedures, any physical limitation that would undermine the safety of the subject in the study, or any psychiatric or neurological condition that inhibits full comprehension of study requirements and inability to complete informed consent, as determined by treating physician

Related Conditions & MeSH terms

• Bladder Cancer
• Cancer
• Circulating Tumor Cell
• Gastrointestinal Cancer
• Gastrointestinal Neoplasms
• Metastasis Lung
• Metastasis to Liver
• Neoplasm Metastasis
• Neoplastic Cells, Circulating

Intervention

Other:
• Blood Draw
A blood sample will be collected once, prior to treatment.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
UNC Lineberger Comprehensive Cancer Center

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correlation between treatment response in CTCs and in vivo	To estimate the agreement between CTC cultures' response to treatment, dichotomized as either yes or no response, to the clinical response in patients to treatment, dichotomized as either progressive disease (PD) versus complete response (CR), partial response (PR), or stable disease (SD)	Initiation of trial to 24 months post-initiation
Secondary	Sensitivity, specificity, and predictive values of CTC cultures' treatment response	To determine the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of CTC cultures' response in predicting clinical response including complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD)	Initiation of trial to 24 months post-initiation